Valbenazine
- Generic Name
- Valbenazine
- Brand Names
- Ingrezza
- Drug Type
- Small Molecule
- Chemical Formula
- C24H38N2O4
- CAS Number
- 1025504-45-3
- Unique Ingredient Identifier
- 54K37P50KH
- Background
Valbenazine is a modified metabolite of tetrabenazine, and it is currently being approved for the treatment of various movement disorders, particularly tardive dyskinesia and chorea associated with Huntington's disease. Tardive dyskinesia has long been regarded as a consequence of anti-dopamine receptor therapy, and until 2008 with the advent of tetrabenazin...
- Indication
Valbenazine is indicated for the treatment of adults with tardive dyskinesia and chorea associated with Huntington’s disease.
- Associated Conditions
- Chorea, Tardive Dyskinesia (TD)
- Associated Therapies
- -
Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome
- Conditions
- Interventions
- First Posted Date
- 2018-05-21
- Last Posted Date
- 2022-05-17
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 81
- Registration Number
- NCT03530293
- Locations
- 🇺🇸
Neuricrine Clinical Site, Sun City, Arizona, United States
🇵🇷Neurocrine Clinical Site, San Juan, Puerto Rico
Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
- First Posted Date
- 2018-02-23
- Last Posted Date
- 2022-02-23
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 85
- Registration Number
- NCT03444038
- Locations
- 🇵🇷
Neurocrine Clinical Site, San Juan, Puerto Rico
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
- First Posted Date
- 2017-10-30
- Last Posted Date
- 2021-06-28
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 127
- Registration Number
- NCT03325010
- Locations
- 🇵🇷
Neurocrine Clinical Site, San Juan, Puerto Rico
Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette Syndrome
- First Posted Date
- 2016-08-25
- Last Posted Date
- 2021-04-29
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 155
- Registration Number
- NCT02879578
Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia
- First Posted Date
- 2016-04-13
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 161
- Registration Number
- NCT02736955
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.